Pengadilan Membuka Bukti Kunci dalam Perkara Coventry yang Menunjukkan Abacus Global Management Mengandalkan Estimasi Harapan Hidup yang Lebih Pendek dari Lapetus dan Menyesatkan Investor

Coventry First and CEO Alan H. Buerger won a court order in Florida requiring Abacus to disclose internal materials in their dispute, alleging investor misrepresentation tied to life-expectancy assumptions used for valuing life insurance policies. The newly revealed data indicates Lapetus’ A/E ratio was only 41.5% vs a near-100% disclosure by leading providers—implying materially higher observed deaths than expected. The filing also alleges Abacus used inconsistent discount-rate assumptions and omitted or distorted at least three key facts in a June 10, 2025 Lewis & Ellis valuation press release following a Morpheus Research short-seller report, a negative catalyst for Abacus’ credibility and secondary-policy valuation practices.

Analysis

This is less about a single lawsuit headline and more about whether the company’s asset marks can survive hostile discovery. In a model-driven business, once the market believes management selectively used the most aggressive inputs and withheld contrary data, the risk premium expands fast because every future valuation, asset sale, and financing becomes suspect. That usually shows up first in multiple compression, then in tighter terms from warehouse lenders and any buyer of portfolio cash flows.

The second-order damage is broader than the equity: counterparties that rely on these marks will likely demand larger haircuts, more frequent re-underwriting, or third-party validation. That can force a slower deployment pace, lower realized spreads, and potentially a negative feedback loop where weaker liquidity makes marks look even more fragile. If the business depends on recurring capital from affiliated vehicles or structured buyers, trust erosion can propagate into fundraising and transaction volume over the next 1-3 months.

Contrarian risk: the market may treat this as merely another litigation overhang and underestimate how quickly discovery can become a balance-sheet story. If management cannot credibly re-anchor valuation methodology, the issue can persist for 6-18 months and cap the stock even if the case itself drags. The key falsifier is not just a legal win, but evidence that third-party purchasers, lenders, or auditors continue to accept the same asset marks without concessions.

Key Decisions for Investors

• Short ABX on strength into legal headlines; use a 1-3 month horizon and cover only if management demonstrates third-party validation of marks or if the stock closes decisively above the post-news reaction high for several sessions.
• Prefer ABX put spreads over outright puts if borrow is expensive: target the next court/disclosure catalyst window, seeking convexity to a rerating but limiting theta if the case drags.
• Watch for financing stress indicators: any widening in debt spreads, tighter warehouse terms, or slower asset turnover would be the earliest confirmation that this is turning from a litigation story into a funding story.
• Avoid long exposure to any peer whose valuation relies on opaque mortality/level-3 inputs until counterparties react; if forced to express a relative view, pair short ABX versus a diversified financials basket rather than a direct sector peer.
• Set an alert for management disclosure that changes methodology, audit posture, or external validation; that would be the main falsifier for the short thesis and likely marks the point to reduce risk quickly.